Accelr8's Q3 Revenues Drop Sharply | GenomeWeb

NEW YORK (GenomeWeb News) – Accelr8 today disclosed that revenues during its fiscal third quarter fell 18-fold quarter over quarter, resulting from the end of an agreement with Novartis.

In its Form 10-Q filed with the US Securities and Exchange Commission, the Denver-based company reported revenues of $13,207 for the three months ended April 30, compared to $240,272 a year ago, as technical development fees came in at $0 for the recent quarter, down from $214,500 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.